PepGen (PEPG)

• Market cap: $52.2M
• 1 day: 7.43%
• 5 days: 0.63%
• 1 month: 23.26%
• 3 months: 6.71%
• 6 months: -32.34%
• Year to date: -57.82%
• 1 year: -82.57%
• 5 years: -87.66%
• 10 years: -87.66%
• Sector: Healthcare
• Industry: Biotechnology

About: PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Employees: 62

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

6.45% less ownership

Funds ownership: 77.45% [Q1] → 70.99% (-6.45%) [Q2]

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

28% less capital invested

Capital invested by funds: $35.6M [Q1] → $25.8M (-$9.79M) [Q2]

28% less funds holding

Funds holding: 72 [Q1] → 52 (-20) [Q2]

80% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 25

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6
• Avg. target: $6
• High target: $6

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Debjit Chattopadhyay

$6

Buy Initiated

9 Sep 2025